儿童肝移植后原发性硬化性胆管炎复发:国际观察性研究
该国际多中心回顾性研究纳入140例因原发性硬化性胆管炎(PSC)接受肝移植的儿童,评估复发(rPSC)危险因素。中位随访3年,rPSC在移植后2年和5年发生率分别为10%和27%。rPSC与移植时年龄更小、PSC诊断至移植进展更快、移植时ALT更高、合并炎症性肠病更常见相关,且移植后急性排斥发作更多、激素难治性排斥更常见,死亡率更高。
要点
- 儿童PSC肝移植后rPSC 2年发生率10%、5年27%,高于既往报道。
- rPSC者移植时更年轻、PSC至移植进展更快、ALT更高,合并IBD更常见。
- rPSC者移植后急性排斥发作更多、激素难治性排斥更常见,死亡风险更高。
核心结论
- 该队列儿童肝移植后rPSC发生率高于既往报道,并与发病率和死亡率增加相关。
- rPSC患者似呈更侵袭性、免疫反应性表型,需理解其免疫机制以开发新疗法。
研究设计与样本
- 回顾性评估儿童PSC联盟(国际多中心注册)中140例因PSC接受肝移植且随访>90天的儿童。
- rPSC主要结局采用Graziadei标准定义,移植后中位随访3年(四分位距1.1-6.1)。
主要发现
- 36例发生rPSC,移植后2年和5年发生率分别为10%和27%。
- rPSC组移植时年龄更小(12.9 vs. 16.2岁),PSC诊断至移植进展更快(2.5 vs. 4.1年),移植时ALT更高(112 vs. 66 IU/L),均P<0.01。
- rPSC组合并炎症性肠病更常见(86% vs. 66%;P=0.025)。
- 移植后rPSC组活检证实的急性排斥发作更多(均值3 vs. 1;P<0.001),激素难治性排斥更常见(41% vs. 20%;P=0.04)。
- rPSC组中43%在诊断后2年内出现门静脉高压并发症、再次列入移植名单或死亡;死亡率更高(11.1% vs. 2.9%;P=0.05)。
关键数值与推荐
- rPSC定义采用Graziadei标准。
- rPSC组移植时年龄12.9 vs. 16.2岁,PSC诊断至移植2.5 vs. 4.1年,移植时ALT 112 vs. 66 IU/L,均P<0.01。
- 炎症性肠病患病率86% vs. 66%(P=0.025);急性排斥均值3 vs. 1(P<0.001);激素难治性排斥41% vs. 20%(P=0.04);死亡率11.1% vs. 2.9%(P=0.05)。
临床怎么用
- 儿童PSC肝移植后应警惕rPSC,尤其移植时年龄小、PSC进展快、ALT高及合并IBD者。
- 移植后反复急性排斥或激素难治性排斥可能提示rPSC风险,需加强监测。
局限性
- 为回顾性研究,样本来自注册数据库,可能存在选择偏倚和信息偏倚。
- rPSC诊断依赖Graziadei标准,未报告中心间诊断一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recurrent primary sclerosing cholangitis (rPSC) following liver transplant (LT) has a negative impact on graft and patient survival; little is known about risk factors for rPSC or disease course in children. APPROACH AND RESULTS: We retrospectively evaluated risk factors for rPSC in 140 children from the Pediatric PSC Consortium, a multicenter international registry. Recipients underwent LT for PSC and had >90 days of follow-up. The primary outcome, rPSC, was defined using Graziadei criteria. Median follow-up after LT was 3 years (interquartile range 1.1-6.1). rPSC occurred in 36 children, representing 10% and 27% of the subjects at 2 years and 5 years following LT, respectively. Subjects with rPSC were younger at LT (12.9 vs. 16.2 years), had faster progression from PSC diagnosis to LT (2.5 vs. 4.1 years), and had higher alanine aminotransferase (112 vs. 66 IU/L) at LT (all P < 0.01). Inflammatory bowel disease was more prevalent in the rPSC group (86% vs. 66%; P = 0.025). After LT, rPSC subjects had more episodes of biopsy-proved acute rejection (mean 3 vs. 1; P < 0.001), and higher prevalence of steroid-refractory rejection (41% vs. 20%; P = 0.04). In those with rPSC, 43% developed complications of portal hypertension, were relisted for LT, or died within 2 years of the diagnosis. Mortality was higher in the rPSC group (11.1% vs. 2.9%; P = 0.05). CONCLUSIONS: The incidence of rPSC in this cohort was higher than previously reported, and was associated with increased morbidity and mortality. Patients with rPSC appeared to have a more aggressive, immune-reactive phenotype. These findings underscore the need to understand the immune mechanisms of rPSC, to lay the foundation for developing new therapies and improve outcomes in this challenging population.
引用
- Martinez M, Perito ER, Valentino P, et al. Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study. Hepatology. 2021. PMID: 34008252. doi:10.1002/hep.31911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。